REFERENCES

1. Rosenson RS. Existing and emerging therapies for the treatment of familial hypercholesterolemia. J Lipid Res. 2021;62:100060.

2. Cuchel M, Raal FJ, Hegele RA, et al. 2023 update on European atherosclerosis society consensus statement on homozygous familial hypercholesterolaemia: new treatments and clinical guidance. Eur Heart J. 2023;44:2277-91.

3. Wiegman A, Bourbon M, Freiberger T, et al. Familial hypercholesterolaemia in children and adolescents: a European Atherosclerosis Society consensus statement. Eur Heart J. 2026;47:3324-46.

4. Ahmad Z, Agarwala A, Cuchel M, et al. Update on familial hypercholesterolemia: an expert clinical consensus from the National Lipid Association. J Clin Lipidol. 2026;20:708-37.

5. Cuchel M, Bloedon LT, Szapary PO, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med. 2007;356:148-56.

6. Raal FJ, Greber-platzer S, Reeskamp LF, et al. Efficacy of evinacumab by genotype and low-density lipoprotein receptor function in patients with homozygous familial hypercholesterolaemia: a subanalysis from the ELIPSE open-label extension study. Atherosclerosis. 2026;414:120657.

7. Raal FJ, Rosenson RS, Reeskamp LF, et al. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med. 2020;383:711-20.

8. Rosenson RS, Burgess LJ, Ebenbichler CF, et al. Evinacumab in patients with refractory hypercholesterolemia. N Engl J Med. 2020;383:2307-19.

9. Rosenson RS, Niu X, Popadic L, et al. Real-world treatment adherence and persistence among patients initiating inclisiran or PCSK9 mAbs. Am J Prev Cardiol. 2026;30:101739.

10. Marnell CS, Koenig W, Bittner V, et al. Barriers and emerging strategies to bridge gaps in implementation of evidence-based lipid-lowering therapies. Circ Popul Health Outcomes. 2026;19:e012330.

11. Wan P, Tang S, Lin D, et al. In vivo base editing gene therapy for heterozygous familial hypercholesterolemia: a phase 1 trial. Nat Med. 2026;32:1045-51.

12. Vafai SB, Täubel J, Ashdown T, et al. In vivo base editing of PCSK9 with VERVE-102 for hypercholesterolemia. N Engl J Med. 2026;395:648-59.

13. Raal FJ, Bergeron J, Gaudet D, et al. Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial. Lancet Diabetes Endocrinol. 2026;14:123-36.

14. Laffin LJ, Nicholls SJ, Scott RS, et al. Phase 1 trial of CRISPR-Cas9 gene editing targeting ANGPTL3. N Engl J Med. 2025;393:2119-30.

15. Rosenson RS, Goonewardena SN. Base editing milestone for familial hypercholesterolemia. Nat Med. 2026;32:812-3.